What Causes Chromosomal Errors in Eggs? The Science Explained Simply

The Biological Blueprint: Understanding Chromosomes and Meiosis

To understand what goes wrong, we first need to understand how things are supposed to work. At the heart of this story are our chromosomes, the biological blueprints that make us who we are, and meiosis, the special type of cell division that prepares eggs and sperm for fertilization.

What Are Chromosomes?

Think of your DNA as a massive library of instruction manuals. Each chromosome is a tightly coiled volume in that library, containing thousands of individual instructions, or genes. In almost every cell in our body, we have 46 of these volumes, arranged in 23 pairs. We inherit one set of 23 chromosomes from our mother and one set of 23 from our father. This complete set of 46 chromosomes is essential for normal human development.

Meiosis: The Special Division for Eggs and Sperm

Because a healthy embryo must have exactly 46 chromosomes, the egg and sperm must each contain exactly half that number: 23. The process of creating these special cells with only 23 chromosomes is called meiosis. It is a remarkable and intricate two-step cell division. In the first stage, Meiosis I, the 23 pairs of chromosomes are separated, so the cell goes from having 46 chromosomes in pairs to having 23 chromosomes, each with a duplicated copy. In the second stage, Meiosis II, these duplicated copies (called sister chromatids) are pulled apart. The end result is a cell with a single set of 23 chromosomes. This process must be perfect. If an egg ends up with even one extra or one missing chromosome, the resulting embryo will be aneuploid, and its chances of developing into a healthy baby are drastically reduced.

The Primary Cause: The Aging of the Egg

While chromosomal errors can occasionally happen in the sperm, the vast majority—over 90%—originate in the egg. And the single biggest risk factor for these errors is maternal age. This is not due to a woman’s lifestyle or health, but rather to the unique and extraordinary biology of the human egg.

A Lifetime on Pause: The Unique Biology of Eggs

A woman is born with all the eggs she will ever have. These eggs are formed during her own fetal development and are arrested in the middle of the first meiotic division (Meiosis I). They remain in this state of suspended animation for years, even decades, until they are recruited for ovulation. This means that the egg that a 40-year-old woman ovulates is, in a biological sense, 40 years old. This long period of dormancy is the root cause of the age-related decline in egg quality.

Cohesin Degradation: When the Chromosome “Glue” Weakens

During this long arrest, the pairs of chromosomes are held together by a complex of proteins called cohesin. You can think of cohesin as a form of biological “glue.” For meiosis to work correctly, this glue must hold the chromosome pairs together securely for potentially decades, and then release them in a highly controlled manner at the exact right moment. The problem is that this glue is not infinitely stable. Over the many years that the egg is waiting, the cohesin proteins slowly degrade and fall off the chromosomes. As a woman gets older, the cohesin holding her eggs’ chromosomes together becomes weaker and more brittle. When the egg finally resumes meiosis just before ovulation, this weakened glue can cause the chromosomes to be pulled apart incorrectly, leading to aneuploidy.

The Spindle Apparatus: A Faltering Biological Machine

The physical work of pulling the chromosomes apart is done by a complex piece of cellular machinery called the spindle apparatus. This is a dynamic structure made of microtubules that attach to the chromosomes and physically segregate them to opposite poles of the cell. In older eggs, the spindle itself can become disorganized and dysfunctional. It may not assemble correctly, or it may not attach to the chromosomes properly. This, combined with the weakened cohesin, creates a “perfect storm” for errors. Imagine trying to untangle a delicate, sticky web with a shaky, misaligned tool—it is a recipe for disaster. This combination of old, brittle “glue” and a faltering biological machine is the primary reason why chromosomal errors are so common in the eggs of older women.

Cellular and Environmental Contributors to Chromosomal Errors

While the aging of the meiotic machinery is the primary driver of chromosomal errors, other cellular and environmental factors can contribute to the problem. These factors can exacerbate the age-related decline and further compromise the egg’s ability to divide correctly, leading to what is clinically known as Poor Egg Quality.

Mitochondrial Dysfunction: An Energy Crisis

Mitochondria are often referred to as the “batteries” or “powerhouses” of the cell, and for good reason. They are responsible for generating the vast majority of the cell’s energy supply in the form of ATP. The process of accurately segregating 46 chromosomes is an incredibly energy-intensive task. The spindle apparatus, in particular, requires a huge amount of ATP to assemble and function correctly. Just like the rest of the cell, the mitochondria within the egg also age. Over time, they can become less efficient and produce less energy. This can create an “energy crisis” within the aging egg. When the egg resumes meiosis, it may not have enough power to run the spindle machinery properly, leading to errors in chromosome segregation. This mitochondrial dysfunction is a key component of the age-related decline in egg quality.

Oxidative Stress and DNA Damage

Our bodies are constantly producing unstable molecules called reactive oxygen species (ROS), or free radicals, as a byproduct of normal metabolism. When the production of these molecules overwhelms the cell’s ability to neutralize them, it leads to a state of oxidative stress. Oxidative stress can damage all components of the cell, including proteins, lipids, and DNA. Over the decades that an egg is held in its arrested state, it is exposed to low levels of oxidative stress. This cumulative damage can take a toll on the delicate machinery of meiosis, including the cohesin proteins and the spindle apparatus, further increasing the risk of errors when the egg finally attempts to divide.

Environmental and Lifestyle Factors

While the internal aging process of the egg is the main culprit, external factors can certainly play a role. Lifestyle choices and environmental exposures can influence the level of oxidative stress in the body and the overall health of the ovarian environment. Factors such as smoking, excessive alcohol consumption, a diet high in processed foods, and exposure to environmental toxins (like BPA and phthalates) can all increase oxidative stress. While these factors are unlikely to be the primary cause of aneuploidy, they can certainly contribute to a less-than-optimal cellular environment, potentially accelerating the age-related decline in egg quality and function.

Can We Detect These Errors? The Promise and Peril of PGT-A

Given the high rate of chromosomal errors in human embryos, it is natural to ask if we can test for them. This desire to select the “best” embryo has led to the widespread use of Preimplantation Genetic Testing for Aneuploidy (PGT-A), a technology that is as promising as it is controversial.

The Goal of Preimplantation Genetic Testing (PGT-A)

The stated goal of PGT-A is to improve IVF outcomes by screening embryos for aneuploidy before they are transferred to the uterus. The idea is that by preferentially transferring only euploid (chromosomally normal) embryos, one can increase the implantation rate, reduce the miscarriage rate, and decrease the time it takes to achieve a pregnancy.

The Embryo biopsy: How a Sample is Taken

The process of PGT-A requires an Embryo biopsy. This is a highly technical procedure performed on a day 5 or day 6 embryo (a blastocyst). A skilled embryologist uses a laser to create a small opening in the shell of the embryo and then carefully removes a small sample of 5-10 cells from the trophectoderm, which is the layer of cells that will eventually form the placenta. These cells are then sent to a genetics lab for analysis.

The Major Controversy: False positives and mosaicism in PGT

Despite its widespread use, PGT-A is a deeply flawed technology. The biggest issue is the high rate of False positives and mosaicism in PGT. A false positive occurs when the test incorrectly labels a healthy, viable embryo as “abnormal,” leading to its discard. This is a devastating outcome, as it means that patients may be throwing away the very embryos that could have led to a healthy baby. The problem is compounded by the biological phenomenon of mosaicism, where an embryo has a mixture of normal and abnormal cells. It is now well-established that the trophectoderm biopsy is often not representative of the inner cell mass (the part that becomes the fetus), and that many mosaic embryos have the remarkable ability to self-correct and develop into perfectly healthy babies. The inability of PGT-A to reliably distinguish between truly abnormal embryos and these viable mosaic ones is its fundamental failing.

Logistical Hurdles: Between the biopsy and PGT lab

Beyond the biological limitations, there are significant practical challenges. The entire process is a delicate chain of events, and there are many points Between the biopsy and PGT lab where errors can occur. The quality of the biopsy, the handling of the tiny DNA sample, the potential for contamination, and the specific technology used by the genetics lab can all impact the accuracy of the result. These pre-analytical risks add another layer of uncertainty to an already imperfect test.

The Future of Embryo Selection: Moving Beyond PGT-A

The significant limitations of PGT-A have created a strong impetus within the reproductive medicine community to find better, safer, and more accurate ways to assess embryo viability. The future lies in non-invasive technologies that look beyond a simple chromosome count to a more holistic evaluation of an embryo’s health and developmental potential.

Acknowledging the Limits of PGT-A

The first step towards progress is acknowledging the shortcomings of our current tools. The high false-positive rate and the complex issue of mosaicism mean that PGT-A, in its current form, is an unreliable and potentially harmful technology. Many leading clinics and researchers are now moving away from the routine use of PGT-A, recognizing that it may be causing more harm than good by leading to the discard of viable embryos.

The Mitochondrial Score and PGT: A New Frontier

One of the most promising areas of research is the assessment of an embryo’s metabolic health. The concept of the Mitochondrial Score and PGT is at the forefront of this new frontier. As we’ve discussed, mitochondria are the energy powerhouses of the cell, and a developing embryo has immense energy requirements. By measuring biomarkers related to mitochondrial function—either from the culture medium the embryo was grown in or from the small amount of fluid within the blastocyst—scientists hope to gain a more accurate picture of an embryo’s viability. An embryo with a healthy and robust energy supply is more likely to have the potential to implant and develop, making this a powerful, non-invasive indicator of its health.

The Power of Artificial Intelligence

Another exciting development is the application of artificial intelligence (AI) to embryology. Many clinics now use time-lapse incubators that take thousands of images of an embryo as it develops from a single cell to a blastocyst. AI algorithms can be trained on vast datasets of these images, learning to identify incredibly subtle patterns in cell division timing and morphology that are predictive of implantation success. These “morphokinetic” parameters are invisible to the human eye but can be powerful predictors of an embryo’s viability. This technology offers the potential for a completely non-invasive, objective, and highly accurate method of embryo selection, rendering the risks and controversies of biopsy obsolete.

Making a decision: What Does This Mean for Patients?

Understanding the science behind chromosomal errors and the limitations of the technologies designed to detect them is crucial for Making a decision on your fertility journey. It empowers you to ask critical questions and to be an active participant in your own care.

Understanding the Root Cause

The most important takeaway is that the vast majority of chromosomal errors are a natural consequence of the egg’s aging process. The degradation of cohesin and the faltering of the meiotic spindle are biological realities that, at present, cannot be reversed. This understanding can help to alleviate the sense of guilt or blame that many women feel when faced with a diagnosis of poor egg quality or a pregnancy loss due to aneuploidy. It is not your fault; it is a feature of human biology.

A Cautious Approach to Testing

Given the significant and well-documented limitations of PGT-A, a cautious approach is warranted. Patients should have a detailed and honest conversation with their doctor about the pros and cons. You should ask about the clinic’s false-positive rate, their policy on transferring mosaic embryos, and whether they offer non-invasive assessment methods. For many patients, particularly those with only a few embryos, the risk of discarding a healthy embryo may outweigh any potential benefit of the test.

Focusing on What Can Be Controlled

Instead of focusing on a flawed genetic test, a more productive approach may be to focus on the factors that can be controlled. This includes optimizing your overall health through nutrition, moderate exercise, and stress management to create the best possible cellular environment for your eggs. It also involves working with your doctor to choose the most appropriate IVF protocol. For an older patient or someone with diminished ovarian reserve, a mild stimulation protocol that focuses on egg quality over quantity may be a more logical and effective approach than an aggressive protocol that could further compromise the delicate meiotic machinery.

Conclusion

The high incidence of chromosomal errors in human eggs is a fundamental challenge in reproductive medicine. It is a problem rooted in the unique biology of the oocyte and the inevitable process of aging. The slow degradation of the cohesin “glue” that holds chromosomes together, combined with an aging cellular machinery, creates a perfect storm for errors during the delicate process of meiosis. While technologies like PGT-A have been developed with the noble goal of identifying these errors, their inherent flaws and the risk of false positives make them a controversial and often unreliable tool. The future of embryo selection is moving towards non-invasive, functional assessments of embryo health, such as metabolic scoring and AI-driven analysis. For patients navigating this complex landscape, the key is knowledge. Understanding the science empowers you to ask the right questions, to be skeptical of promises that seem too good to be true, and to make informed decisions that are aligned with your personal goals and values.

References

1.Poor Egg Quality: A clinical term for diminished oocyte viability, often associated with advanced maternal age and low ovarian reserve.

2.False positives and mosaicism in PGT: A discussion on the limitations and controversies of preimplantation genetic testing.

3.Mitochondrial Score and PGT: An overview of emerging technologies for assessing embryo viability beyond chromosomal status.

4.Embryo biopsy: A guide to the procedure of taking a cell sample from an embryo for genetic testing.

5.Between the biopsy and PGT lab: An outline of the logistical risks and potential for error in the handling of biopsied cells.

6.Making a decision: Guidance on the decision-making process regarding the use of PGT-A in IVF.